SV investment has resulted in the approval of 24 novel therapeutics
SV News
14 November 2024Portfolio NewsTRexBio Announces $84 Million Series B Financing to Advance Pipeline of First-in-Class Immunology Programs into Clinical Development
31 October 2024SV NewsSV is hiring: Executive Assistant
8 October 2024Portfolio NewsMestag Therapeutics Announces License and Research Collaboration with MSD to Identify Novel Targets for Inflammatory Diseases
8 October 2024Portfolio NewsData Presented at the American College of Chest Physicians Correlates Airway Remodeling with Positive Clinical Outcomes Utilizing the RejuvenAir® System
3 October 2024Portfolio NewsEnara Bio raises $32.5 million Series B financing to advance first-in-class pipeline of TCR-based immunotherapies targeting novel Dark Antigens®
2 October 2024Portfolio NewsLoQus23 Therapeutics announces £35 million (c.$43 million) Series A financing to advance its small molecule somatic expansion inhibition therapy for Huntington's disease
24 September 2024Portfolio NewsQuell Therapeutics Expands Manufacturing Capabilities for CAR-Treg Cell Therapy Pipeline Through Partnership with eXmoor pharma
19 September 2024Portfolio NewsPrilenia Appoints Rob Lauzen as Chief Financial Officer and Jason Marks as Chief Legal Officer
11 September 2024SV NewsSpectraWAVE Announces $50M Series B Financing to Drive Commercial Expansion and Product Additions to the HyperVue™ Imaging System- 3 September 2024Portfolio NewsPrilenia’s Pridopidine for Huntington’s Disease Accepted for European Marketing Authorisation Review
3 September 2024Portfolio NewsAmphista Therapeutics appoints Antony Mattessich as Chief Executive Officer- 28 August 2024Portfolio NewsMestag Therapeutics Awarded Significant Grant from Innovate UK’s Prestigious Cancer Therapeutics Program to Accelerate the Path to the Clinic for MST-0300
